Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Arcus Biosciences Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active prosecution is limited to 1 distinct examiner and 1 distinct art unit. LAU, JONATHAN S is the busiest examiner, managing 1 busiest examiner pending action.
The presence of 1 pending office action indicates a focused prosecution phase for the company. With 1 distinct examiner, LAU, JONATHAN S, handling the 1 busiest examiner pending action, the company's progress in the Biotechnology & Pharmaceuticals sector is currently dependent on the outcome of this single examination process. Practitioners should prioritize the specific feedback from LAU, JONATHAN S, as this examiner oversees the entire current workload of pending actions. Since the activity is restricted to 1 distinct art unit, the prosecution strategy can be highly specialized. Successfully navigating the 1 pending office action is the primary goal for the portfolio at this time, as it represents the only active path toward securing patent rights in the identified Biotechnology & Pharmaceuticals technology area. The 1 distinct examiner will determine the results.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.8% | -17.1% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18490434 | LYOPHILIZED FORMULATIONS OF CD73 COMPOUNDS | LAU, JONATHAN S | 1693 | §103 | Non-Final OA | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArcus Biosciences Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jonathan S Lau has the most, with 1 of Arcus Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.